Table 1 Demographics and clinical characteristics for the metastatic RCC patients
Variables | All patients (n = 2315) | Training set (n = 1158) | Validation set (n = 1157) |
|---|---|---|---|
No. (%) | No. (%) | No. (%) | |
Age (years) | 61 (54–68) | 60 (54–68) | 61 (54–68) |
Race | |||
 White | 1941 (83.8%) | 968 (83.6%) | 973 (84.1%) |
 Black | 174 (7.5%) | 92 (7.9%) | 82 (7.1%) |
 Other | 200 (8.6%) | 98 (8.5%) | 102 (8.8%) |
Sex | |||
 Male | 1629 (70.4%) | 812 (70.1%) | 817 (70.6%) |
 Female | 686 (29.6%) | 346 (29.9%) | 340 (29.4%) |
Marital status | |||
 Married | 1559 (67.3%) | 777 (67.1%) | 782 (67.6%) |
 Unmarried | 756 (32.7%) | 381 (32.9%) | 375 (32.4%) |
Histologic subtype | |||
 CCRCC | 1959 (84.6%) | 982 (84.8%) | 977 (84.4%) |
 PRCC | 142 (6.1%) | 56 (4.8%) | 86 (7.4%) |
 CHRCC | 27 (1.2%) | 14 (1.2%) | 13 (1.1%) |
 SRCC | 168 (7.3%) | 91 (7.9%) | 77 (6.7%) |
 CDRCC | 19 (0.8%) | 15 (1.3%) | 4 (0.3%) |
Fuhrman grade | |||
 Grade I | 57 (2.5%) | 26 (2.2%) | 31 (2.7%) |
 Grade II | 516 (22.3%) | 247 (21.3%) | 269 (23.2%) |
 Grade III | 926 (40.0%) | 482 (41.6%) | 444 (38.4%) |
 Grade IV | 816 (35.2%) | 403 (34.8%) | 413 (35.7%) |
Tumor size (mm) | 90 (70–118) | 90.5 (70–120) | 90 (68–115) |
Tumor classification | |||
 T1 | 289 (12.5%) | 141 (12.2%) | 148 (12.8%) |
 T2 | 383 (16.5%) | 198 (17.1%) | 185 (16.0%) |
 T3 | 1316 (56.8%) | 661 (57.1%) | 655 (56.6%) |
 T4 | 293 (12.7%) | 143 (12.3%) | 150 (13.0%) |
 TX | 34 (1.5%) | 15 (1.3%) | 19 (1.6%) |
Lymph node status | |||
 N0 | 1618 (69.9%) | 796 (68.7%) | 822 (71.0%) |
 N1 | 597 (25.8%) | 310 (26.8%) | 287 (24.8%) |
 NX | 100 (4.3%) | 52 (4.5%) | 48 (4.1%) |
Sarcomatoid feature | |||
 Yes | 446 (19.3%) | 220 (19.0%) | 226 (19.5%) |
 No | 1697 (73.3%) | 848 (73.2%) | 849 (73.4%) |
 Unknown | 172 (7.4%) | 90 (7.8%) | 82 (7.1%) |
Cancer-directed surgery | |||
 Recommended and performed | 1982 (85.6%) | 980 (84.6%) | 1002 (86.6%) |
 Recommended but not performed | 21 (0.9%) | 12 (1.1%) | 9 (0.6%) |
 Not recommended | 312 (13.5%) | 166 (14.3%) | 146 (12.8%) |
Bone metastasis | |||
 Yes | 729 (31.5%) | 361 (31.2%) | 368 (31.8%) |
 No | 1586 (68.5%) | 797 (68.8%) | 789 (68.2%) |
Brain metastasis | |||
 Yes | 230 (9.9%) | 112 (9.7%) | 118 (10.2%) |
 No | 2085 (90.1%) | 1046 (90.3%) | 1039 (89.8%) |
Liver metastasis | |||
 Yes | 254 (11.0%) | 126 (10.9%) | 128 (11.1%) |
 No | 2061 (89.0%) | 1032 (89.1%) | 1029 (88.9%) |
Lung metastasis | |||
 Yes | 1429 (61.7%) | 723 (62.4%) | 706 (61.0%) |
 No | 886 (38.3%) | 435 (37.6%) | 451 (39.0%) |